Call Us @ 0172 - 4680800 | info@indswift.com | NSE - BSE
Corona Remedies acquires two brands from Abbott
 
Ahmedabad: City-based pharma firmCorona Remedies today announced the acquisition of Obimet andThyrocab brands, comprising of 14 product line extensions, from Abbott India.
Both these brands are popular prescription drugs to manage diabetes and hyperthyroidism, Tejas Kothari, Head-Strategy at Corona said.

"This is the second brand acquisition by the company in the past year. Both these brands acquired by us are expected to garner a sales revenue of around Rs 25 crore in the first year of integration," Kothari told media persons here today while making the announcement.

In addition to the acquisitions, the company has also announced to set up its second manufacturing facility at Bavla village near Ahmedabad.

At present, the company is having its manufacturing facility in Himachal Pradesh.

"Our existing plant in Himachal Pradesh is having a manufacturing capacity of 100 crore tablets, 6 crore capsules and one crore liquid bottles per annum," said Vijay Charlu, vice president of sales and marketing.
"Now, we are setting up our second plant at Bavla with an investment of Rs 60 crore. The new plant will mostly cater to the European market. It will become operational by the end of 2019. This plant will produce 200 crore tablets, 60 crore capsules and 3 crore liquid bottles" said Charlu.

(Et health world)
 
Other Related News:
2019 FDA Approved Drugs
FDA announces another carcinogenic impurity in ARB blood pressure drugs
Researchers identify common genetic signature among three rare skin diseases
Health ministry to amend Section 71 of D&C Rules to make Pharm D professionals eligible to supervise drug manufacturing
3rd International Diabetes Summit to be held in Pune from March 8-10, 2019
Health ministry to roll out common IT platform for management of sales and manufacturing licenses of drugs
Cosmetics licences may come with product composition details to enhance safety; new clause proposed in Cosmetics Rules 2018
T-cell specificity found to play a role in attacks on myelin versus β-synuclein in MS
Plazomicin noninferior to meropenem for complicated UTI
New molecules reverse memory loss linked to depression, aging